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Abstract
Background: The use of platelet rich plasma (PRP, GLO) has been used as an adjunct to various regenerative dental
procedures. The aim of the present study was to characterize the influence of PRP on human gingival fibroblasts,
periodontal ligament (PDL) cells and osteoblast cell behavior in vitro.
Methods: Human gingival fibroblasts, PDL cells and osteoblasts were cultured with conditioned media from PRP
and investigated for cell migration, proliferation and collagen1 (COL1) immunostaining. Furthermore, gingival
fibroblasts were tested for genes encoding TGF-β, PDGF and COL1a whereas PDL cells and osteoblasts were
additionally tested for alkaline phosphatase (ALP) activity, alizarin red staining and mRNA levels of osteoblast
differentiation markers including Runx2, COL1a2, ALP and osteocalcin (OCN).
Results: It was first found that PRP significantly increased cell migration of all cells up to 4 fold. Furthermore, PRP
increased cell proliferation at 3 and 5 days of gingival fibroblasts, and at 3 days for PDL cells, whereas no effect was
observed on osteoblasts. Gingival fibroblasts cultured with PRP increased TGF-β, PDGF-B and COL1 mRNA levels at
7 days and further increased over 3-fold COL1 staining at 14 days. PDL cells cultured with PRP increased Runx2
mRNA levels but significantly down-regulated OCN mRNA levels at 3 days. No differences in COL1 staining or ALP
staining were observed in PDL cells. Furthermore, PRP decreased mineralization of PDL cells at 14 days post
seeding as assessed by alizarin red staining. In osteoblasts, PRP increased COL1 staining at 14 days, increased COL1
and ALP at 3 days, as well as increased ALP staining at 14 days. No significant differences were observed for alizarin
red staining of osteoblasts following culture with PRP.
Conclusions: The results demonstrate that PRP promoted gingival fibroblast migration, proliferation and mRNA
expression of pro-wound healing molecules. While PRP induced PDL cells and osteoblast migration and
proliferation, it tended to have little to no effect on osteoblast differentiation. Therefore, while the effects seem to
favor soft tissue regeneration, the additional effects of PRP on hard tissue formation of PDL cells and osteoblasts
could not be fully confirmed in the present in vitro culture system.
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Background
Various regenerative modalities in modern dental medi-
cine have been investigated in recent years with the aim
of either speeding hard or soft tissue regeneration or
optimising the regenerative outcomes [1–4]. One of
these modalities frequently promoted has been the
utilization of growth factors including platelet derived
growth factor (PDGF) and bone morphogenetic proteins
(BMPs) [4, 5]. While the use of such growth factors has
been shown to speed the quality of either hard or soft
tissue formation specifically when combined with vari-
ous biomaterials including barrier membranes and bone
grafting materials, some disadvantages such as high
costs, high supra-physiological doses of growth factors,
as well as unwanted side effects associated with recom-
binant therapies have also been reported [6–8].
Interestingly, the use of platelet rich plasma (PRP) con-
tains plasma with up to a 5-fold increase in platelet
concentrations [9], has been shown to improve growth
factor concentrations from whole blood by centrifugation
to reach supra-physiological doses [10, 11]. Reported
advantages include having higher biocompatibility as
well as relatively low costs associated with their treatment
[12–17]. Initial experiments revealed that PRP contained
high levels of PDGF compared to whole blood capable of
modulating tissue wound healing [9, 17–21]. Other investi-
gators have hypothesized that bone healing could be
improved due to the angiogenetic, proliferative and/or dif-
ferentiating effects of PRP on various cell types [19, 22–24].
While initial experiments hypothesized over such advan-
tages, data from the literature have shown mixed results
following the use of PRP as a regenerative material for bone
and periodontal regeneration [17, 25–39].
Since PRP has now been utilized in the field of peri-
odontology for over a decade with various results, the
aim of the present study was to perform one of the
largest known in vitro studies on the topic by utilizing 3
different cell-types involved with periodontal regeneration
including human gingival fibroblasts, osteoblasts and peri-
odontal ligament (PDL) cells. Currently, there remains
controversial results for studies that have attempted to de-
termine the bone-healing and soft tissue-healing potential
of PRP. Therefore, this in vitro study was utilized to better
characterize the regenerative potential of conditioned
media from a new formulation of PRP (GLO PRP) on each
cell type with direct comparison over their regenerative
potential being possible within the same study.
Methods
Platelet concentrates
Blood samples were harvested with the informed con-
sent of 6 volunteer donors (from Bern Switzerland) and
further processed into PRP. No IRB was required for the
present study as blood was used in a non-identifiable
manner and the IRB waived its requirement (Bern,
Switzerland). The PRP was prepared utilizing the GLO
PRP kit. Briefly, 1 ml of sodium citrate anticoagulant
was added into the GLO PRP tube and 9 ml of blood
was then taken from the donor. Thereafter the red blood
cell collector was attached firmly on the tip of the GLO
PRP tube and the plunger removed by turning it counter
clockwise and the blood + anticoagulant was shaken gen-
tly. The first centrifuge was then performed at 1200 g
for 5 min and thereafter the remaining red blood cells
were flushed out from the tube to separate them. The
remaining tube was re-centrifuged for a second time at
1200 g for 10 min. Thereafter, platelet poor plasma
(PPP) and PRP were separated using a 5 ml syringe with
needle to collect the PPP. The remaining PRP was fur-
ther utilized for experimental seeding as later indicated.
Blood was collected from members of our laboratory
(30 to 60 years of age).
Thereafter PRP was transferred to 6 well culture dishes
with 5 mL of cell culture media and processed for fur-
ther investigation as previously described [40–42]. PRP
was incubated for 3 days in a spinning chamber at 37 °C
and conditioned media (CM) was collected and utilized
for future experiments as a 20% total volume dose.
Protein quantification with ELISA
ELISA was utilized to quantify the total amount of
growth factors released from PRP at 15 min, 60 min,
8 h, 1 day, 3 days and 10 days. All PRP samples were
harvested and placed in a shaking incubator at 37 °C
where growth factors were gradually released over time
and collected from standard tissue culture media. At
each time point, media was collected and replaced with
a fresh 5 mL of media and frozen for later processing.
Standing ELISA was utilized to quantify proteins accord-
ing to the manufacturer’s protocols as previously de-
scribed [43]. Absorbance was measured at 450 and
570 nm on an ELx808 Absorbance Reader (BIO-TEK,
Winooski, VT) and samples were quantified in triplicate
with 3 independent experiments performed.
Cell isolation and culture
Primary human gingival tissues were obtained from
three healthy donors under-going third molar extraction
as previous described [44]. Similarly, primary osteoblasts
were also cultured from bone tissue during removal of
impacted 3rd molars as previously described [45, 46]. Pri-
mary human PDL cells were harvested from the middle
third portion of healthy extracted teeth (for normal
standard care) with no signs of periodontal disease ex-
tracted for orthodontic reasons as previously described
[45, 46]. Cells from each tissue type (1. gingival fibro-
blasts, 2. osteoblasts and 3. PDL cells) were collected from
3 separate donors and pooled with similar cell-types. No
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IRB was required for the present study as cells were col-
lected in a non-identifiable manner and the IRB waived its
requirement (Bern, Switzerland). An ethical approval with
informed written consent was obtained from all patients.
All cells were detached from tissue culture plastic using
0.25% EDTA-Trypsin (Gibco, Life technologies, Carlsbad,
CA) prior to reaching confluency. Cells were cultured in a
standard humidified atmosphere at 37 °C in of DMEM
(Gibco), 10% fetal bovine serum (FBS; Gibco) with 1%
antibiotics (Gibco). Cells (passage 4–6) were seeded with
20% conditioned media from PRP for experimental pur-
poses as previously described [47]. 10,000 cells were
utilized for cell proliferation experiments and 50,000 cells
were utilized for real-time PCR, immunofluorescent stain-
ing, ALP assay and alizarin red experiments in 24 well
culture dishes.
Cell viability
Primary human gingival fibroblasts, PDL cells and osteo-
blasts were seeded at a density of 10’000 cells per 24-well
plate on control tissue culture plastic, with 20% con-
ditioned media from PRP and 10% FBS. At 24 h post
cell seeding, a live-dead staining assay was used to as-
sess cell viability (Enzo Life Sciences AG; Lausen,
Switzerland) as previously described [48]. Thereafter,
the percentage of live versus dead cells was utilized
to quantify cell viability.
Cell migration assay
A Boyden chamber was utilized to investigate migration
of cells using 24-well plates and polyethylene terephthalate
filters with a pore size of 8 μm (ThinCertTM, Greiner
Bio-One GmhH, Frickenhausen, Germany). PRP condi-
tioned media (20%) in DMEM containing 10% FBS was
placed into the lower wells as previously described [40,
49]. After starving the cells in DMEM containing 0.5%
FBS for 12 h, 10,000 cells were seeded in the upper com-
partment and after 24 h, the number of migrated cells on
the lower side of the filter were counted under a micro-
scope as previously described [40, 49].
Proliferation assay
Ten thousand primary human gingival fibroblasts, PDL
cells and osteoblasts were seeded in 24-well culture
plates with 20% conditioned media from PRP. An MTS
assay was utilized to quantify cells (Promega, Madison,
WI) at 1, 3 and 5 days as previously described [46, 50].
At desired time points, cells were washed with phos-
phate buffered solution (PBS) and quantified using a
ELx808 Absorbance Reader.
Real-time PCR analysis
Total RNA was harvested at 3 and 7 days post stimulat-
ing for gingival fibroblasts to investigate mRNA levels of
TGF-β, PDGF-A, PDGF-B and collagen1a2 (COL1a2).
For PDL cells and osteoblasts, osteoblast differentiation
markers including Runx2, COL1a2, alkaline phosphat-
ase (ALP) and osteocalcin (OCN) mRNA levels were in-
vestigated at 3 and 14 days post-seeding. Table 1 reports
the primer and probe sequences for genes. RNA isolation
(High Pure RNA Isolation Kit, Roche, Switzerland) and
real-time RT-PCR (Roche Master mix on an Applied Bio-
systems 7500 Real-Time PCR machine) was then per-
formed. A Nanodrop 2000c (Thermo, Wilmington, DE)
was utilized to calculate total RNA levels. The ΔΔCt
method was utilized to calculate gene expression levels
normalized to the expression of GAPDH.
ALP activity assay
PDL cells and osteoblasts were stimulated with 20%
conditioned media from PRP with and without osteo-
genic differentiation medium (ODM), which consisted of
DMEM supplemented with 10% FBS, 1% antibiotics,
50 μg/ml ascorbic acid (Sigma, St. Louis, MO) and
10 mM β-glycerophosphate (Sigma) to induce osteoblast
differentiation as previously described [51]. The ALP
assay was performed using the Leukocyte alkaline pho-
sphatase kit (procedure No. 86, Sigma) as previously
described [45, 52–55].
Mineralization assay
Alizarin red staining was used to determine osteoblast
mineralization. After 14 days, cells were stained followed
by 0.2% alizarin red solution staining (pH 6.4) as previ-
ously described [45, 50, 51, 56, 57].
Table 1 List of primer sequences for real-time PCR
Gene Primer Sequence
hTGF-β F actactacgccaaggaggtcac
hTGF-β R tgcttgaacttgtcatagatttcg
hPDGF-A F cacacctcctcgctgtagtattta
hPDGF-A R gttatcggtgtaaatgtcatccaa
hPDGF-B F tcccgaggagctttatgaga
hPDGF-B R actgcacgttgcggttgt
hCOL1a2 F cccagccaagaactggtatagg
hCOL1a2 R ggctgccagcattgatagtttc
hRunx2 F tcttagaacaaattctgcccttt
hRunx2 R tgctttggtcttgaaatcaca
hALP F gacctcctcggaagacactc
hALP R tgaagggcttcttgtctgtg
hOCN F agcaaaggtgcagcctttgt
hOCN R gcgcctgggtctcttcact
hGAPDH F agccacatcgctcagacac
hGAPDH R gcccaatacgaccaaatcc
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Collagen immunofluorescent staining
Human gingival fibroblasts, PDL cell and osteoblasts
were plated at a density of 50,000 cells per structure in a
24-well plate containing 20% conditioned media from
PRP. At 14 days post seeding, cells were fixed and
stained with collagen type I antibodies (sc-28657, Santa
Cruz, California, USA) diluted 1:100 in PBS containing
1% BSA as previously described.
Statistical analysis
Three independent experiments performed in triplicate
were utilized for all conditions. Means and standard
errors (SE) were calculated and data were analyzed for
statistical significance using standard t-test (2 groups),
one way analysis of variance (ANOVA) with Tukey test
by GraphPad Prism 6.0 software.
Results
Release of growth factors from PRP
In a first series of experiments, the total amount of
growth factors released from PRP including PDGF-AA,
PDGF-AB, PDGF-BB, TGF-β1, VEGF, IGF and EGF was
investigated at various time points including 15 min,
60 min, 8 h, 1 day, 3 days, and 10 days. It was found that
of all the growth factors, PDGF-AA released the highest
total amount of growth factor followed by TGF-β1
(Fig. 1). Interestingly, most of the growth factor release
occurred at early time points (15 and 60 min), whereas
little release of growth factor was seen at later time
points up to a 10 day period. Figure 1b demonstrates the
total growth factor release accumulated in the culture
media over a 10 day period. The release of VEGF, IGF
and EGF followed similar trends whereby growth factor
release occurred at early time points (15 and 60 min)
and was maintained up to a 10 day period (data not
shown). The total growth factor release from each donor
is summarized in Table 2 along with the minimum, max-
imum and average values.
Cell viability of gingival fibroblasts, PDL cells and
osteoblasts in response to PRP
In a first set of experiments, we sought to characterize
the influence of conditioned media from PRP on cell
viability of 3 cell types including gingival fibroblasts,
PDL cells and osteoblasts (Fig. 2). It was found that all
cells displayed no significant changes in cell viability
following 24 h cell culture with and without PRP. There-
fore, it was initially confirmed that PRP is fully biocom-
patible under the present in vitro cell culture model and
future experiments were designed thereafter to investi-
gate its effect on cell behaviour (Figs. 3, 4 and 5).
Influence of PRP on human gingival fibroblasts
Following cell survival investigation, conditioned media
from PRP was then investigated on gingival fibroblast
cell behaviour (Fig. 3). It was first observed that PRP
induced a 4-fold significant increase in cell migration of
gingival fibroblasts at 24 h (Fig. 3a). Furthermore, PRP
Fig. 1 Growth factor release from PRP over time. a growth factor release of PDGF-AA, PDGF-AB, PDGF-BB and TGF-β1 at various time points.
b Total growth factor release over a 10-day period
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also significantly increased cell proliferation of gingival
fibroblasts at 3 and 5 days post seeding (Fig. 3b). Real
time PCR demonstrated that PRP significantly increased
regenerative mRNA levels of growth factors including
TGF-β, PDGF-B and COL1a2 at 7 days post seeding
(Fig. 3c). Immunofluorescent staining of COL1 at 14 days
further demonstrated a 300% increase in COL1 staining
when compared to gingival fibroblasts cultured on con-
trol tissue culture plastic without PRP (Fig. 3d, e).
Influence of PRP on human PDL cells
Thereafter, conditioned media from PRP was investigated
on PDL cell behaviour (Fig. 4). It was found that PRP sig-
nificantly increased cell migration at 24 h (Fig. 4a) and cell
proliferation at 3 days (Fig. 4b) however the effects were
much less pronounced when compared to gingival fi-
broblasts. Real time PCR for osteoblast differentiation
markers including genes encoding Runx2, COL1a2, ALP
and OCN did not seem to show any trend towards im-
proving their differentiation towards osteoblasts/cemento-
blasts by demonstrating no changes in COL1a2 and ALP
mRNA levels at both 3 and 14 days post seeding (Fig. 4c).
Interestingly, PRP significantly increased mRNA levels of
Runx2 at 3 days, however not at 14 days, whereas mRNA
levels of OCN were significantly down-regulated at 3 days
with no differences found at 14 days (Fig. 4c).
Thereafter, COL1 immunofluorescent staining as well
as ALP staining showed no preference for PRP when
compared to control tissue culture plastic (Fig. 4d, e).
PRP also failed to promote the mineralization potential
of PDL cells at 14 days by demonstrating significantly
lower levels of alizarin red staining at 14 days post seed-
ing (Fig. 4f ).
Influence of PRP on human osteoblasts
Lastly, the effect of conditioned media from PRP was
investigated on human osteoblasts (Fig. 5). It was first
observed that PRP significantly increased osteoblast
migration at 24 h (Fig. 5a). No effect on osteoblast
proliferation was seen at either 1, 3 or 5 days post
seeding (Fig. 5b). Real-time PCR demonstrated that
PRP significantly increased COL1a2 and ALP mRNA
levels at 3 days, as well as Runx2 mRNA levels at
14 days post seeding (Fig. 5c). No significant differ-
ence in OCN mRNA levels was observed at either 3
or 14 days post-seeding following osteoblast culture
with PRP (Fig. 5c).
Table 2 Total growth factors released over 10 days from PRP.
Data represents averages (pg/ml) with ranges (minimum to
maximum values)
PRP – minimum PRP – average PRP - maximum
PDGF-AA 5968 8954 15787
PDGF-AB 1644 3522 8179
PDGF-BB 415 1020 2761
TGF-β1 366 4909 12414
VEGF 187 331 486
EGF 77 182 344
IGF 511 987 1728
Fig. 2 Live/Dead assay of PRP. Live/Dead assay at 24 h of primary human gingival fibroblasts (GF) (a, b), PDL cells (PDL) (c, d) and osteoblasts
(OB) (e, f) in response to cell culture with PRP. No significant changes in cell viability were observed for all platelet concentrates
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Fig. 3 Effect of PRP on human gingival fibroblasts. Human primary gingival fibroblast cultured with PRP on (a) cell migration at 24 h, (b)
proliferation at 1, 3 and 5 days, (c) real-time PCR at 3 and 7 days for mRNA levels of TGF-β, PDGF-A, PDGF-B and COL1a2, as well as (d, e)
immunofluorescent collagen1 (COL1) staining at 14 days. (Data presents means and standard error bars; * denotes significant difference
between groups, p < 0.05)
Fig. 4 Effect of PRP on human periodontal ligament cells. Human PDL cells cultured with PRP on (a) cell migration at 24 h, (b) cell proliferation at
1, 3 and 5 days, (c) real-time PCR at 3 and 14 days for mRNA levels of osteoblast differentiation markers including Runx2, COL1a2, ALP and OCN,
(d) immunofluorescent COL1 staining at 14 days, (e, f) ALP staining both with and without osteoblast differentiation media (ODM) at 14 days, as
well as (f) alizarin red staining denoting mineralization at 14 days post seeding. (Data presents means and standard error bars; * denotes significant
difference between groups, p < 0.05)
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Thereafter, it was found that PRP significantly pro-
moted a 2.5 fold increase in COL1 immunofluorescent
staining at 14 days post seeding (Fig. 5d). Interestingly,
ALP staining without ODM found that PRP significantly
decreased ALP staining whereas with ODM significantly
promoted ALP staining at 14 days (Fig. 5e). No change
in alizarin red staining was observed following osteoblast
culture with PRP (Fig. 5f ).
Discussion
The aim of the present study was to investigate the in
vitro regenerative potential of conditioned media from
PRP on 3 different cell-types involved in periodontal re-
generation including gingival fibroblasts, PDL cells and
osteoblasts. To date, no study has performed such a wide-
spread in vitro analysis on the performance of PRP (from
GLO systems) on these cell-types. Furthermore, new spin
cycle protocols and various formulation of platelet con-
centrates are routinely brought to market and it is there-
fore of clinical interest and significance to investigate their
individual performances [15, 47, 58, 59].
Recently, we investigated the release of various growth
factors from 3 different platelet concentrates [58]. It was
first found that PRP, in comparison to PRF, released higher
amounts of growth factors including PDGF, TGF-β and
VEGF at early time points (15 and 60 min) and therefore
favoured the early release of growth factors for regenerative
procedures [58]. In the present study, we also found that
this different formulation of PRP, spun with pre-existing
columns to separate platelet concentrates, also formulated
a PRP with a release profile of growth factors similar to pre-
vious formulations of PRP. Interestingly however, a slight
increase in total growth factor, most likely resulting from
the present system utilized was noticed.
The concentrated growth factors released from PRP
was then investigated on the migration and proliferation
of various cell-types from the oral cavity (Figs. 2, 3 and 4).
Interestingly, it was found that gingival fibroblasts dem-
onstrated the ability to further promote cell migration
and proliferation in response to PRP when compared to
PDL cells and osteoblasts. Furthermore, COL1 staining
was also more significantly upregulated in gingival fibro-
blasts when compared to PDL cells and osteoblasts.
Interestingly, it was observed that PRP had no effect on
the ALP activity of PDL cells and actually significantly
down-regulated in vitro mineralization potential of PDL
cells by demonstrating lower levels of alizarin red staining
(Fig. 4) whereas its effect on osteoblasts demonstrated
Fig. 5 Effect of PRP on human osteoblasts. Human osteoblasts cultured with PRP on (a) cell migration at 24 h, (b) cell proliferation at 1, 3 and
5 days, (c) real-time PCR at 3 and 14 days for mRNA levels of osteoblast differentiation markers including Runx2, COL1a2, ALP and OCN,
(d) immunofluorescent COL1 staining at 14 days, (e, f) ALP staining both with and without osteoblast differentiation media (ODM) at
14 days, as well as (f) alizarin red staining denoting mineralization at 14 days post seeding. (Data presents means and standard error
bars; * denotes significant difference between groups, p < 0.05)
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little to no changes in mineralization potential (Fig. 5). It
may therefore be concluded that while PRP showed little
to no potential to induce osteoblast differentiation (new
bone formation), its effects seemed to favour gingival
fibroblast regeneration (soft tissue wound healing). Future
animal models are however necessary to further confirm
these in vitro findings.
Over the years, numerous investigations have been per-
formed to determine the regenerative potential of PRP for
both soft and hard tissue regeneration [60–62]. For in-
stance, Graziani et al. previously investigated the biological
rationale of PRP by evaluating its effect at different concen-
trations on fibroblasts and osteoblasts activity in vitro [62].
It was found that PRP preparations exerted a dose-specific
effect on oral fibroblasts and osteoblasts. Interestingly, in-
creased concentrations resulted in a reduction in prolifera-
tion and a suboptimal effect on osteoblast function
primarily [62]. Griffin et al. showed in a systematic review
that although early clinical results suggest that the use of
PRP is safe and feasible, however presents with no clinical
benefit in either acute or delayed fracture healing was ob-
served and therefore its use in bone regeneration was not
undetermined [61]. While other models have also shown
favorable results on new bone formation with platelet con-
centrates [63–65], the results from our study showed that
PRP had little influence on osteoblast differentiation (Fig. 5).
Therefore and in combination with some of the previous
published studies, it may be suggested that PRP induced a
strong potential for soft-tissue regeneration by demonstrat-
ing marked increases in gingival fibroblast cell migration,
proliferation, release of growth factor and collagen synthesis
(Fig. 3) yet has no obvious potential to induce or enhance
new bone formation. Although several advantages existed
when PRP was combined with PDL cells and osteoblasts
including increased cell migration, proliferation or collagen
synthesis, these marked increases were less pronounced
and did not seem to contribute to their differentiation or
mineralization potential at least in vitro.
Conclusions
The results from the present study demonstrated that PRP
is able to release supra-physiological doses of platelet-
derived growth factors including PDGF-AA, PDGF-AB,
PDGF-BB, TGF-β1, VEGF, EGF and IGF at varying concen-
trations for up to 10 days. While PRP was extremely bio-
compatible with all cell-types, it can be hypothesized that
PRP is able to induce greater soft tissue regeneration by
significantly increasing the stimulation of gingival fibroblast
behaviour when compared to PDL cells or osteoblasts. Lit-
tle effects, however, were observed for PRP on osteoblasts
differentiation or mineralization potential of PDL cells and
osteoblasts in vitro. Future animal testing is thus required
to further evaluate the regenerative potential of PRP in both
soft and hard tissue formation.
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